Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The Albumin-Creatinine Ratio (ACR) is a key biomarker for early kidney disease detection and is predictive of chronic kidney disease (CKD) progression and associated cardiovascular risks. Antioxidant diets, indicated by the Composite Dietary Antioxidant Index (CDAI), may reduce oxidative stress and alter albumin urinary excretion rates. This study explores the relationship between CDAI and albuminuria.
Materials And Methods: Data on intake of vitamins A, C, E, zinc, selenium, and beta-carotene from the NHANES database (2007-2018) were used to compute CDAI scores. To measure urinary albumin, the ACR levels were assessed. The association between CDAI and ACR was analyzed through multivariate logistic regression, subgroup analysis, and interaction tests, incorporating a generalized additive model (GAM) to evaluate potential non-linear relationships.
Results: A total of 28,601 participants were included with an average CDAI of 0.302 ± 3.895. Those in higher CDAI quartiles showed a reduced likelihood of elevated ACR. The prevalence of increased ACR decreased across the CDAI quartiles from 13.89% in Q1 to 10.11% in Q4. Higher CDAI scores were inversely related to ACR (OR: 0.99, 95% CI: 0.97-1.00), with a significant interaction effect by BMI ( = 0.0048). In males, a distinct L-shaped relationship was noted, with a negative correlation between CDAI and ACR to the left of the inflection point at 0.53 (OR: 0.95, 95% CI: 0.91-0.98).
Conclusion: Increasing CDAI is associated with lower ACR and reduced risk of albuminuria, suggesting that dietary antioxidants may benefit renal and cardiovascular health.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985420 | PMC |
| http://dx.doi.org/10.3389/fnut.2025.1552889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treating rheumatoid arthritis in Zanzibar: a cost effectiveness study comparing conventional, biologic, and targeted-synthetic disease modifying anti-rheumatic drugs.
Front Med (Lausanne)
August 2025
Department of Global Public Health and Primary Care, Bergen Center for Ethics and Priority Settings (BCEPS), Bergen, Norway.
Rheumatoid arthritis is a chronic inflammatory joint disease with low treatment coverage in sub-Saharan Africa. Effective treatment strategies are available. We aimed to evaluate the cost effectiveness of six disease modifying anti-rheumatic drug (DMARD) treat-to-target treatment strategies for patients with rheumatoid arthritis in Zanzibar.
View Article and Find Full Text PDFAssociation of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid Arthritis.
ACR Open Rheumatol
July 2025
Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Objective: To investigate whether soluble immune checkpoint molecules in blood are associated with the treatment response to disease-modifying antirheumatic drugs in early rheumatoid arthritis (eRA).
Methods: This study included 328 Swedish treatment-naïve patients with eRA from the Nordic Rheumatic Diseases Strategy Trials and Registries (NORD-STAR) study. Patients were randomized into four treatment groups: methotrexate (MTX) combined with CTLA-4Ig (n = 90), anti-tumor necrosis factor (n = 83), anti-interleukin-6 receptor (n = 76), or prednisolone (n = 79).
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis.
PLoS One
August 2025
Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Objective: To determine whether baseline CD4+ T helper (Th) cell subset proportions in blood may serve as predictive biomarkers for achieving remission 48 weeks after initiating CTLA-4Ig, anti-tumor necrosis factor (TNF), or anti-interleukin 6 receptor (IL6R) treatment in patients with early rheumatoid arthritis (eRA).
Methods: This study included 60 untreated eRA patients from the larger randomized treatment trial NORD-STAR. They were treated with methotrexate (MTX) combined with either CTLA-4Ig (n = 17), anti-TNF (n = 22), or anti-IL6R (n = 21).
Relationship between heart rate variability parameters and inflammatory activity in patients with Crohn's disease: a retrospective study.
PeerJ
August 2025
Department of Anesthesiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Background: It is widely recognized that individuals with Crohn's disease (CD) often experience impaired autonomic nervous system (ANS) function. However, the specific relationship between autonomic activity and inflammatory processes in CD remains uncertain. The objective of this study was to investigate the association between autonomic nervous function, as assessed through heart rate variability (HRV) parameters, and the Crohn's disease activity index (CDAI).
View Article and Find Full Text PDFArtificial Intelligence for Quantifying Endoscopic Mucosal Ulceration in Crohn's Disease.
Clin Gastroenterol Hepatol
August 2025
Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA; Michigan Institute for Data Science, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Background & Aims: Endoscopic scoring of Crohn's disease (CD) is challenging as mucosal disease is patchy with highly variable morphology, size, and severity. Computer vision may help quantify disease activity with similar performance as standard instruments like the Simple Endoscopic Score for Crohn's Disease (SES-CD).
Methods: Colonoscopy videos from the STARDUST and SEAVUE phase 3 clinical trials underwent post-hoc computer vision endoscopic (CVE) assessment to quantify CD mucosal ulceration and injury.